Last update 09 Feb 2026

BL-M14D1

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
BL M14D1, BL-M25D1, BLM14D1
Target
DLL3 x Top I
Action
inhibitors
Mechanism
DLL3 inhibitors(Delta-like protein 3 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors)
Therapeutic Areas
NeoplasmsInfectious DiseasesRespiratory Diseases+ [1]
Active Indication
DLL3 positive Small Cell Lung CancerLarge cell neuroendocrine carcinoma of lungMetastatic Merkel Cell Carcinoma+ [2]
Inactive Indication-
Originator Organization
Sichuan Biokin Pharmaceutical Co., Ltd.Sichuan Biokin Pharmaceutical Co., Ltd.
Active Organization
Sichuan Baili Pharmaceuticals Co.,LtdSichuan Baili Pharmaceuticals Co.,LtdBaili Bio Chengdu Pharmaceutical Co. Ltd.Systimmune, Inc.Systimmune, Inc.
+ [1]
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

2
Clinical Trials associated with BL-M14D1
NCT07080242
/ RecruitingPhase 1
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Tumors
NCT06505824
/ RecruitingPhase 1
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics and Preliminary Efficacy of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
100 Clinical Results associated with BL-M14D1
Login to view more data
100 Translational Medicine associated with BL-M14D1
Login to view more data
100 Patents (Medical) associated with BL-M14D1
Login to view more data
100 Deals associated with BL-M14D1
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
DLL3 positive Small Cell Lung CancerPhase 1
United States
Systimmune, Inc.Systimmune, Inc.
28 Apr 2025
Large cell neuroendocrine carcinoma of lungPhase 1
United States
Systimmune, Inc.Systimmune, Inc.
28 Apr 2025
Metastatic Merkel Cell CarcinomaPhase 1
United States
Systimmune, Inc.Systimmune, Inc.
28 Apr 2025
Neuroendocrine TumorsPhase 1
China
Sichuan Baili Pharmaceuticals Co.,LtdSichuan Baili Pharmaceuticals Co.,Ltd
02 Aug 2024
Small Cell Lung CancerPhase 1
China
Sichuan Baili Pharmaceuticals Co.,LtdSichuan Baili Pharmaceuticals Co.,Ltd
02 Aug 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free